Given the importance of identifying prodromes of dementia with specific etiologies, we assessed whether seven latent classes of mild cognitive impairment (MCI), defined empirically based on cognitive, functional, and neuropsychiatric information at initial visit, are associated with distinct clinical outcomes and neuropathological features. We separated 6034 participants with a baseline diagnosis of MCI into seven latent classes using previously defined criteria. We found that these latent classes of MCI differed significantly in their clinical outcomes, survival time, and neuropathology. Two amnestic multi-domain subgroups, as well as two other subgroups with functional impairments and neuropsychiatric disturbances, were at higher risk of not only a 'pure' form of Alzheimer's disease (AD) pathology, but also a 'mixed' pathology consisting of both AD and vascular features. Moreover, the seven latent classes had different risks of Lewy bodies, hippocampal sclerosis, and frontotemporal lobar degeneration (FTLD). This study indicates that data-driven subgroups of MCI are clinicopathologically informative and, with refinement, could lead to targeted interventions focused on each etiology.
Introduction
Advances in AD drug development have led to late-stage clinical trials of potentially disease-modifying therapies. Unfortunately, to date, none of these trials has achieved their primary outcome measures (Cummings et al., 2017; Doody et al., 2014; Salloway et al., 2014) . In parallel, biomarker studies in both sporadic and autosomal-dominant genetic forms of AD have yielded compelling evidence that dementia due to AD represents the product of a pathological process spanning two decades (Bateman et al., 2012; Jack et al., 2013) . The primary target of current therapeutic development, the Aβ peptide that accumulates in senile plaques, is among the earliest lesions in the brains of individuals who develop AD. Since there is ample evidence that antiamyloid therapeutics achieve target engagement and clearance of Aβ (Nicoll et al., 2003; Sevigny et al., 2016) , a plausible explanation for the failure in these clinical trials is that Aβ must be eliminated earlier in the course of disease to produce clinical benefit.
MCI represents an important syndromic entity that encompasses early stages of decline associated with neurodegenerative diseases including AD (Abner et al., 2017; Morris et al., 2001; Petersen et al., 2001; Sperling et al., 2011) . While specific criteria and definitions of MCI vary, they generally include significant decline in one or more cognitive domains with relative preservation of functional activities of daily living. When MCI is seen in conjunction with biological markers, such as CSF levels of Aβ and the microtubule-associated protein Tau, that reliably predict the presence of AD pathology, it represents a prodromal stage of AD. Importantly, efforts to develop effective diseasemodifying treatments for AD have increasingly focused on identifying and enrolling participants with MCI due to prodromal AD. As symptoms of MCI can be produced by a broad range of etiologies, biomarker
